Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

Crucell Holland, B.V. (a Janssen Pharmaceutical Company) Newtonweg 1 2333 CP Leiden P.O. Box 2048 2301 CA Leiden The Netherlands NLD

UEI: SLED_51FE8966B1BDAB24

Crucell Holland, B.V. (a Janssen Pharmaceutical Company) Newtonweg 1 2333 CP Leiden P.O. Box 2048 2301 CA Leiden The Netherlands NLD is a federal contractor, registered under UEI SLED_51FE8966B1BDAB24. It has been awarded $69,023,170 across 1 federal contract. Primary work spans Research and Development in Biotechnology.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_51FE8966B1BDAB24

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

$69.0M100%

Awards by NAICS

541711 - Research and Development in Biotechnology$69.0M100%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in Crucell Holland, B.V. (a Janssen Pharmaceutical Company) Newtonweg 1 2333 CP Leiden P.O. Box 2048 2301 CA Leiden The Netherlands NLD's top NAICS codes and agencies

In Vitro ADMET AssaysThe contract titled In Vitro ADMET Assays calls for the performance of high-throughput in vitro screening focused on metabolic stability, hepatotoxicity, CYP450 enzyme interactions, and cellular permeability to support early-stage drug development. These assays are critical for evaluating the absorption, distribution, metabolism, excretion, and toxicity profiles of potential therapeutic candidates, enabling informed decisions before advancing compounds into costly clinical stages. The work will be conducted to meet the specific needs of the National Institutes of Health NIDA under the Department of Health and Human Services, with performance expected to occur in Bethesda. This is a subcontract opportunity under NAICS code 541711, which classifies it as research and development in the physical, engineering, and life sciences. The solicitation was posted on August 3, 2026, with a response deadline of August 18, 2026, at 7:00 PM Eastern Time. There is no set-aside classification specified, and no point of contact or detailed office address is provided in the data. Interested parties must submit their proposals before the deadline to be considered for award, with the expectation that the selected contractor will deliver reliable, scalable, and scientifically rigorous ADMET data to guide NIDA’s research initiatives in drug development.

National Institutes Of Health Nida

POSTED

DEADLINE

Genotoxicity and Carcinogenicity TestingThe contract seeks to perform in vitro and in vivo assays to assess the mutagenic and carcinogenic risks of drug candidates, ensuring compliance with regulatory safety standards for pharmaceutical development. The work is critical for identifying potential genetic toxicity and cancer-causing properties early in the drug evaluation process to support regulatory submissions and public health safeguards. The solicitation is issued as a subcontract under the National Institutes of Health NIDA, part of the Department of Health and Human Services, with performance expected to take place in Bethesda. It falls under the NAICS code 541711 for research and development in the physical, engineering, and life sciences. The proposal must be submitted by August 18, 2026, with the opportunity posted on August 3, 2026. No set-aside provisions are specified, and the contract is open to qualified subcontractors with the technical capacity to deliver high-quality genotoxicity and carcinogenicity testing services.

National Institutes Of Health Nida

POSTED

DEADLINE

Safety Pharmacology (CNS, Cardiovascular, Pulmonary)The contract requires comprehensive safety pharmacology studies to evaluate adverse effects on the central nervous system, cardiovascular system, and pulmonary function, ensuring alignment with ICH safety guidelines. The work will involve detailed pharmacodynamic assessments to identify and characterize potential risks to major organ systems during early drug development, with a focus on identifying safety signals that could impact clinical translation. This subcontract, issued by the National Institutes of Health’s NIDA under the Department of Health and Human Services, is set to be performed in Bethesda and has a response deadline of August 18, 2026. The effort is classified under NAICS code 541711, indicating it pertains to research and development in the life sciences, and is aimed at supporting regulatory-compliant preclinical safety evaluations essential for pharmaceutical advancement.

National Institutes Of Health Nida

POSTED

DEADLINE

Toxicity Testing (Acute, Subacute, Subchronic, Chronic)The contract requires the performance of comprehensive toxicity testing in both rodent and non-rodent models to assess organ toxicity and establish safety margins for submission to regulatory authorities as part of an Investigational New Drug application. The scope includes acute, subacute, subchronic, and chronic studies designed to evaluate the potential adverse effects of pharmaceutical compounds across a range of exposure durations and dosages. The work must meet rigorous scientific standards to support regulatory filings and ensure the safety profile of investigational drugs is adequately characterized prior to human trials. This subcontract is issued under the National Institutes of Health, National Institute on Drug Abuse, within the Department of Health and Human Services, with the performance location specified as Bethesda. The North American Industry Classification System code 541711 identifies the work as research and development in the life sciences. The solicitation was posted on August 3, 2026, with a mandatory response deadline of August 18, 2026, at 7:00 PM. No set-aside provisions are specified, and the contract opportunity is open to eligible contractors capable of executing preclinical toxicology studies to support IND submissions.

National Institutes Of Health Nida

POSTED

DEADLINE

In Vivo Pharmacokinetic StudiesThe contract seeks to perform in vivo pharmacokinetic studies to assess the absorption, distribution, metabolism, and excretion of a drug candidate in both rodent and non-rodent species across multiple administration routes, with the goal of generating data to support an Investigational New Drug application. These studies will evaluate drug exposure over time to establish pharmacokinetic profiles critical for regulatory submission, requiring rigorous experimental design, appropriate species selection, and adherence to good laboratory practices. All work must be completed to ensure high-quality, reproducible results that meet FDA expectations for preclinical development. The solicitation is classified as a subcontract under NAICS code 541711, issued by the National Institutes of Health through the National Institute on Drug Abuse, part of the Department of Health and Human Services. Performance is expected to take place in Bethesda, and interested parties must submit their responses no later than August 18, 2026, at 7:00 PM. The opportunity was posted on August 3, 2026, and is open for competitive bidding with no specific set-aside designation. The contract does not provide a point of contact, and all inquiries must be directed through the official SAM.gov portal linked in the posting.

National Institutes Of Health Nida

POSTED

DEADLINE

Influenza Vaccine Clinical Trial ManagementThe contract pertains to the design and management of Phase I–III clinical trials for influenza vaccines, encompassing all critical aspects from protocol development and site selection to patient recruitment and regulatory reporting to the FDA. The work requires specialized expertise in infectious disease trials, with a focus on ensuring compliance with regulatory standards and timely submission of clinical data. The performance location is in Washington, DC, with a zip code of 20024, indicating the primary operational base for trial oversight and coordination. This is a subcontract under the Department of Health and Human Services, specifically managed by Barda – ASPR / DAAPPO / Barda DCMA, with a NAICS code of 541711 indicating scientific research and development services. The opportunity was posted on July 30, 2026, with a response deadline of August 15, 2026, at 9:00 PM ET. While no set-aside type or point of contact is specified, the emphasis on end-to-end clinical trial management suggests the subcontractor must possess a proven track record in vaccine development, regulatory engagement, and multi-site trial execution under federal health security initiatives.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Clinical Trial Design and Efficacy Data GenerationThe contract calls for the design and execution of clinical trials aimed at evaluating the safety, wound closure, infection control, and functional regeneration outcomes of medical interventions in patients with burn and trauma injuries. The work requires rigorous scientific methodology to generate robust efficacy data that supports regulatory and clinical adoption, with a focus on measurable endpoints related to tissue recovery and patient outcomes. The trials must be conducted in accordance with established clinical standards and are intended to provide evidence of therapeutic effectiveness under real-world conditions. This is a subcontract under the Aspr Administration for Strategic Preparedness and Response, part of the Department of Health and Human Services, with a solicitation posted on July 28, 2026, and a response deadline of August 28, 2026. The work is classified under NAICS code 541711, indicating research and development in the life sciences. The performance location is designated with a zip code of 77416, though no specific city or state is provided, and no point of contact details are listed. The contract does not include a set-aside designation, and all eligible entities may respond, with emphasis placed on technical capability, trial design expertise, and experience in trauma and burn clinical research.

Aspr Administration For Strategic Preparedness And Response

POSTED

DEADLINE

Induced Pluripotent Stem Cell (iPSC) Reprogramming ServicesThe contract entails the reprogramming of human articular chondrocytes and bone marrow cells into induced pluripotent stem cells using Sendai virus technology, with full support for culture expansion and cryopreservation of the resulting iPSCs. This subcontract is part of a research initiative led by the Department of Veterans Affairs through Rpo East, focused on advancing regenerative medicine techniques through advanced cellular reprogramming methods. The work requires precise adherence to protocols ensuring high efficiency, safety, and scalability of iPSC generation while maintaining cell viability and pluripotency throughout the process. The solicitation is open for responses until August 6, 2026, and falls under NAICS code 541711, indicating it is for research and development in the biological sciences. The agreement is structured as a subcontract, suggesting it will be awarded to a specialized contractor with expertise in stem cell biology and virology-based reprogramming. Performance is expected to meet rigorous quality standards for cellular products intended for potential therapeutic or diagnostic applications, with an emphasis on reproducibility and documentation. All deliverables must include verified iPSC lines archived through cryopreservation, ready for downstream use in future studies or clinical translation.

Rpo East (36C24E)

POSTED

DEADLINE

in about 15 hours

Emerging Animal & Zoonotic Disease Diagnostics Research

Sci Technology Acq Division

POSTED

DEADLINE

Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Collaborative Biomedical Research ExecutionThis contract enables a collaborative biomedical research effort focused on neurofibromatosis, requiring coordinated hypothesis-driven investigations led by an Initiating Principal Investigator and a Partnering Principal Investigator. The work encompasses the design of experiments, generation of empirical data, and rigorous milestone-based progress reporting to ensure scientific rigor and accountability. The project is structured as a subcontract under the Defense Health Agency Contracting Activity, falling under the NAICS code for research and development in the physical, engineering, and life sciences, and is intended to advance understanding of neurofibromatosis through integrated scientific contributions. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is managed by the Department of Defense through its health research infrastructure. While no set-aside provisions or specific location details are provided, the emphasis is firmly on outcome-driven research with clearly defined deliverables tied to research milestones. The effort requires close alignment between the two principal investigators to ensure cohesive experimental planning, data integrity, and timely reporting, reflecting a strategic investment in translational medical science with potential implications for defense-relevant health conditions.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Collaborative Research Partnership (Partnering PI Option)This contract establishes a collaborative research partnership where a Partnering Principal Investigator from an external institution will co-lead the research effort alongside the primary team, sharing equal responsibility for scientific direction, project management, and deliverables. Funding is jointly allocated between the participating institutions, ensuring aligned resources and mutual accountability for outcomes, with the work focused on health-related research under the Defense Health Agency Contracting Activity. The initiative falls under NAICS code 541711, indicating it is within the scientific research and development sector, and is structured as a subcontract to support integrated, multi-institutional innovation. The opportunity was posted on June 18, 2026, with a deadline for responses set for September 28, 2026, providing potential partners a defined window to submit proposals. The partnership is expected to be conducted in alignment with the mission of the Department of Defense, addressing critical health priorities through joint scientific leadership. There is no set-aside designation specified, meaning eligibility is open to qualified institutions regardless of size or status, and no specific location is designated for performance, allowing flexibility in where the research activities are carried out as long as the objectives are met collaboratively.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 2 months ago

DEADLINE

in about 2 months

Kidney Cancer Clinical Research ExecutionThe contract titled Kidney Cancer Clinical Research Execution aims to advance clinical and translational research focused on kidney cancer through comprehensive scientific activities including study design, patient data collection, biomarker analysis, and therapeutic development. The work is intended to support the development of innovative treatments and diagnostic strategies by integrating clinical observations with laboratory research, ensuring findings are rapidly translated into improved patient outcomes. The project requires expertise in oncology research methodologies, rigorous data management, and interdisciplinary collaboration to address critical gaps in kidney cancer understanding and care. This subcontract is issued by the Defense Health Agency Contracting Activity under the Department of Defense and falls under NAICS code 541711, indicating it is related to research and development in the life sciences. The opportunity was posted on June 18, 2026, with a response deadline of September 28, 2026, providing potential applicants approximately three months to prepare and submit proposals. The place of performance and specific office address details are not specified, suggesting flexibility in location but requiring proposers to align with the overarching objectives of the Department of Defense’s medical research priorities. All work must demonstrate scientific excellence, feasibility, and direct relevance to advancing kidney cancer therapeutics within a clinical context.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 2 months ago

DEADLINE

in about 2 months

Clinical Trial Design and Biostatistical SupportThe contract seeks specialized expertise to support clinical trial design and biostatistical analysis for orthopaedic trauma research funded by the Department of Defense, specifically under the U.S. Army Medical Research and Acquisition Activity. The work involves developing robust clinical trial methodologies, crafting statistical analysis plans, performing power analyses to ensure adequate sample sizes, and establishing data monitoring frameworks to ensure trial integrity and compliance with regulatory standards. Support must be tailored to the unique challenges of military-relevant trauma studies, including patient populations, deployment-related injuries, and the operational constraints of DoD medical settings. The opportunity is structured as a subcontract with a NAICS code of 541711, indicating it falls under research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, and responses are due by November 18, 2026. Performance is expected to occur within the broader DoD infrastructure, though no specific location is designated. There is no set-aside classification specified, and the contract is open to qualified entities capable of delivering high-level biostatistical and clinical trial methodological support in a defense medical research context.

Department Of The Army -- Usamraa

POSTED

about 2 months ago

DEADLINE

Preclinical Biomedical Research on Traumatic Orthopaedic InjuriesThis contract requires the conduct of preclinical biomedical research focused on bone healing, tissue regeneration, and orthopaedic trauma models using animal systems, with the goal of advancing medical solutions aligned with military needs. The work involves designing controlled experiments, collecting longitudinal data on injury response and recovery, and performing rigorous statistical and biological analysis to evaluate therapeutic interventions. All research must be tailored to simulate combat-related orthopaedic injuries and produce actionable insights applicable to field medical care and soldier recovery protocols. The effort is structured as a subcontract under the Department of the Army through USAMRAA, with a solicitation posted on June 17, 2026, and a response deadline of November 18, 2026. The project falls under NAICS code 541711 for research and development in the physical, engineering, and life sciences. Performance location and point of contact details are not specified, but the research must be executed in facilities capable of supporting high-standard animal modeling and biomechanical analysis. The ultimate objective is to generate validated preclinical data to inform the development of next-generation treatments for traumatic injuries sustained in military operations.

Department Of The Army -- Usamraa

POSTED

about 2 months ago

DEADLINE

Nanobody-Drug Conjugate Systems DevelopmentThe contract pertains to the licensing of the NanoFET platform to develop targeted nanobody-drug conjugates for the precision delivery of therapeutics using a modular scaffold designed to enhance specificity and efficiency in therapeutic distribution. This subcontract, issued by the Department of Energy through its contractor Triad, enables the recipient to leverage the proprietary NanoFET technology for advancing next-generation drug delivery systems with a focus on oncology and other targeted disease treatments. The project is centered in Los Alamos, New Mexico, with a response deadline of December 18, 2026, and falls under the NAICS code 541711 for research and development in biotechnology. The modular scaffold allows for customizable conjugation of nanobodies with therapeutic payloads, facilitating high-affinity targeting of disease markers while minimizing off-target effects. The agreement emphasizes technological innovation and the translation of advanced nanoscale platforms into clinically viable delivery systems.

Triad - DOE Contractor

POSTED

about 2 months ago

DEADLINE

Infectious Disease Vaccine DevelopmentThe contract involves licensing the NanoFET platform to enable rapid-response vaccine development against viral and bacterial pathogens, leveraging its unique adjuvant-free immune activation and modular antigen integration capabilities. This technology allows for swift adaptation to emerging infectious threats by streamlining the design and production of vaccines without relying on traditional immune-stimulating additives, significantly reducing development timelines and enhancing safety profiles. The work is structured as a subcontract under the Department of Energy, with performance centered at Los Alamos, New Mexico, and is targeted toward advancing national defense and public health preparedness through next-generation vaccine platforms. The opportunity is open for proposals until December 18, 2026, and falls under NAICS code 541711, indicating it targets research and development in the physical, engineering, and life sciences. The contracting entity is Triad, the DOE Contractor, and the initiative aligns with broader federal efforts to build resilient, scalable biodefense capabilities. Participants must demonstrate technical proficiency in the NanoFET platform, experience in infectious disease vaccine design, and the capacity to execute rapid development cycles under strict timelines. Success in this effort will contribute directly to scalable, next-generation immunization technologies capable of addressing current and future biological threats.

Triad - DOE Contractor

POSTED

about 2 months ago

DEADLINE

Modular Cancer Immunotherapy DevelopmentThe contract entails the license and development of the NanoFET platform for the creation of targeted cancer immunotherapies, leveraging its modular scaffold to deliver tumor-specific antigens and immune stimulators in a precise and effective manner. The work is focused on advancing next-generation immunotherapeutic approaches by engineering the platform to enhance immune recognition and response against cancer cells, with the goal of improving therapeutic outcomes and reducing off-target effects. The project requires collaboration to optimize the platform’s design, validate its efficacy in preclinical models, and prepare for subsequent clinical translation, all grounded in cutting-edge nanotechnology and immunological science. The contract is a subcontract under the Department of Energy, with performance centered in Los Alamos, New Mexico, 87545, and is classified under NAICS code 541711 for research and development in the physical, engineering, and life sciences. The solicitation was posted on June 17, 2026, with a response deadline of December 18, 2026, indicating a strategic timeline for proposal submission and evaluation. While details on set-aside status and point of contact are not provided, the project is positioned to align with national priorities in advanced biomedical innovation and cancer treatment, leveraging federal research infrastructure and expertise to drive transformative therapeutic solutions.

Triad - DOE Contractor

POSTED

about 2 months ago

DEADLINE